Teduglutide for pediatric short bowel syndrome patients

Rosete, Beatrice E; Wendel, Danielle; Horslen, Simon

doi:10.1080/17474124.2021.1913052

Cited by 16 publications

(5 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Interventions aimed at reducing PN have shown promise in enhancing patient QoL in previous studies. [45][46][47][48] For example, drugs such as Ted has been demonstrated to enhance structural and functional integrity of the remaining intestine in SBS, could improve patients' QoL by reducing patients' use or dependence on HPN/PN, thereby relieving patients' chronic state of limitation. 48,49 Yet, the precise relationship between reduced PN and improved QoL in SBS patients remains enigmatic.…”

Section: Discussionmentioning

confidence: 99%

A Systematic Review of Quality of Life in Patients with Short Bowel Syndrome and Their Caregivers

Chen,

Yan,

Chen

et al. 2024

PPA

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

A Systematic Review of Quality of Life in Patients with Short Bowel Syndrome and Their Caregivers

Chen,

Yan,

Chen

et al. 2024

PPA

View full text Add to dashboard Cite

“… 8 – 10 Compared with hGLP-2, GLP-2 analogs contain one or more substitutes for specific components of natural peptides; additionally, they both retain the pharmacological activity of natural GLP-2 and exhibit a more stable structure, longer half-life, and stronger bonding with targets. 11 Among the three analogs, TED has been approved for clinical use, whereas GLE and APRA still in the experimental stage.…”

Section: Glp-2 and Its Analogsmentioning

confidence: 99%

“…GLP-2 analogs represent the first successful pharmacological intervention that safely and effectively augments the natural process of adaptation and provides a clinical benefit in terms of a reduction in PN volume in patients with SBS. 46 , 47 Its long-term side effects are unknown, and they can only be observed through long-term follow-up. TED is recommended for adults and >1-year-old children with SBS under the condition that the benefits and the known and unknown risks of TED are conveyed to patients.…”

Section: Glp-2 Analog Treatment Strategymentioning

confidence: 99%

An updated overview of glucagon-like peptide-2 analog trophic therapy for short bowel syndrome in adults

Zhu

2022

J Int Med Res

View full text Add to dashboard Cite

Short bowel syndrome (SBS) is a clinical condition characterized by a failure to achieve optimal intestinal adaptation, which is necessary to maintain oral/enteral autonomy. At present, the treatment options for SBS are primarily intestinal replacement and rehabilitation. Intestinal rehabilitation mainly includes non-transplantation surgery and intestinal rehabilitation measures. In recent years, intestinal rehabilitation in patients with SBS using nutritional intestinal hormones, especially glucagon-like peptide-2 analogs, has made great progress. Many high-quality studies have provided evidence-based medical findings to support the development of clinical guidelines. This article reviews the latest research advancements regarding the use of glucagon-like peptide-2 analogs (teduglutide, glepaglutide, and apraglutide) in the treatment of SBS.

show abstract

“…GPR40 partial agonist AS2034178 was reported to resolve dextran sulfate sodium (DSS)-induced colitis in mice, which is mediated by induction of GLP-2 in the gut and in turn induced proliferation of epithelium and promoted healing of DSS-induced colitis ( Kato et al, 2019 ). Indeed, long-lasting GLP-2 analogs have been approved or are being developed for SBS ( Rosete et al, 2021 ; Naimi et al, 2022 ). Villumsen et al performed a retrospective analysis of T2D patients with IBD, treatment of GLP-1-based therapies (GLP-1RAs and DPP4 inhibitors) lowered the risk of adverse clinical events related to IBD by 50% ( Villumsen et al, 2021 ).…”

Section: Gut-restrictive Gpr40 Agonist For Metabolic Disorders and Be...mentioning

confidence: 99%

Learn from failures and stay hopeful to GPR40, a GPCR target with robust efficacy, for therapy of metabolic disorders

Guan¹,

Xiong²

2022

Front. Pharmacol.

View full text Add to dashboard Cite

GPR40 is a class A G-protein coupled receptor (GPCR) mainly expressed in pancreas, intestine, and brain. Its endogenous ligand is long-chain fatty acids, which activate GPR40 after meal ingestion to induce secretion of incretins in the gut, including GLP-1, GIP, and PYY, the latter control appetite and glucose metabolism. For its involvement in satiety regulation and metabolic homeostasis, partial and AgoPAM (Positive Allosteric Modulation agonist) GPR40 agonists had been developed for type 2 diabetes (T2D) by many pharmaceutical companies. The proof-of-concept of GPR40 for control of hyperglycemia was achieved by clinical trials of partial GPR40 agonist, TAK-875, demonstrating a robust decrease in HbA1c (-1.12%) after chronic treatment in T2D. The development of TAK-875, however, was terminated due to liver toxicity in 2.7% patients with more than 3-fold increase of ALT in phase II and III clinical trials. Different mechanisms had since been proposed to explain the drug-induced liver injury, including acyl glucuronidation, inhibition of mitochondrial respiration and hepatobiliary transporters, ROS generation, etc. In addition, activation of GPR40 by AgoPAM agonists in pancreas was also linked to β-cell damage in rats. Notwithstanding the multiple safety concerns on the development of small-molecule GPR40 agonists for T2D, some partial and AgoPAM GPR40 agonists are still under clinical development. Here we review the most recent progress of GPR40 agonists development and the possible mechanisms of the side effects in different organs, and discuss the possibility of developing novel strategies that retain the robust efficacy of GPR40 agonists for metabolic disorders while avoid toxicities caused by off-target and on-target mechanisms.

show abstract

Teduglutide for pediatric short bowel syndrome patients

Cited by 16 publications

References 33 publications

A Systematic Review of Quality of Life in Patients with Short Bowel Syndrome and Their Caregivers

A Systematic Review of Quality of Life in Patients with Short Bowel Syndrome and Their Caregivers

An updated overview of glucagon-like peptide-2 analog trophic therapy for short bowel syndrome in adults

Learn from failures and stay hopeful to GPR40, a GPCR target with robust efficacy, for therapy of metabolic disorders

Contact Info

Product

Resources

About